- Home
- UPST vs CYTK Comparison
UPST vs CYTK Comparison
Compare UPST & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPST
- CYTK
- Stock Information
- Founded
- UPST 2012
- CYTK 1997
- Country
- UPST United States
- CYTK United States
- Employees
- UPST N/A
- CYTK N/A
- Industry
- UPST Finance: Consumer Services
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- UPST Finance
- CYTK Health Care
- Exchange
- UPST Nasdaq
- CYTK Nasdaq
- Market Cap
- UPST 5.8B
- CYTK 5.0B
- IPO Year
- UPST 2020
- CYTK 2004
- Fundamental
- Price
- UPST $71.77
- CYTK $50.26
- Analyst Decision
- UPST Buy
- CYTK Strong Buy
- Analyst Count
- UPST 14
- CYTK 17
- Target Price
- UPST $72.25
- CYTK $82.00
- AVG Volume (30 Days)
- UPST 7.6M
- CYTK 1.9M
- Earning Date
- UPST 02-11-2025
- CYTK 02-27-2025
- Dividend Yield
- UPST N/A
- CYTK N/A
- EPS Growth
- UPST N/A
- CYTK N/A
- EPS
- UPST N/A
- CYTK N/A
- Revenue
- UPST $676,961,000.00
- CYTK $3,219,000.00
- Revenue This Year
- UPST $22.17
- CYTK N/A
- Revenue Next Year
- UPST $20.01
- CYTK $754.18
- P/E Ratio
- UPST N/A
- CYTK N/A
- Revenue Growth
- UPST 23.43
- CYTK N/A
- 52 Week Low
- UPST $20.60
- CYTK $40.53
- 52 Week High
- UPST $96.43
- CYTK $81.36
- Technical
- Relative Strength Index (RSI)
- UPST 49.41
- CYTK 58.40
- Support Level
- UPST $80.02
- CYTK $45.05
- Resistance Level
- UPST $89.64
- CYTK $48.30
- Average True Range (ATR)
- UPST 5.79
- CYTK 2.80
- MACD
- UPST 0.66
- CYTK 0.61
- Stochastic Oscillator
- UPST 32.41
- CYTK 86.80
About UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.